Melanocortin Receptor Subtypes: A Lab Guide to MC1R-MC5R Selectivity
The five melanocortin receptor subtypes, MC1R to MC5R, respond to one family of natural ligands, which makes this system one of the clearest examples of why selectivity has to be designed rather than assumed. For a lab running receptor panels, every published ratio depends on the assay, the cell background and the reference compound behind it. This article sets out how the subtypes differ, which structural changes in synthetic analogs shift their preferences, where selectivity experiments usually go wrong, and what a QC or purchasing team should check when a panel of cyclic analogs arrives in quantity.
Melanocortin receptor subtypes side by side
All five belong to class A of the G-protein-coupled receptor superfamily and are compact even by class A standards, with short extracellular loops and a minimal N-terminal region. Ligands are recognised inside the transmembrane bundle rather than by a large extracellular domain.
| Subtype | Main expression reported | Point to note in the lab |
|---|---|---|
| MC1R | Melanocytes, several immune cell types | Human and rodent forms differ noticeably in ligand recognition |
| MC2R | Adrenal cortex | Responds to ACTH only, and needs MRAP1 to reach the cell surface |
| MC3R | Mainly central nervous system | Signalling tuned by MRAP2 and by an endogenous inverse agonist |
| MC4R | Mainly central nervous system | Shows measurable constitutive activity |
| MC5R | Exocrine glands | Often left out of panels, which weakens selectivity claims |
One precursor, many ligands, little natural selectivity
The endogenous agonists are all cut from a single precursor, pro-opiomelanocortin (POMC). Processing yields alpha-, beta- and gamma-MSH plus ACTH, and every one of them carries the same four-residue recognition sequence, His-Phe-Arg-Trp. Because the receptors read that shared core, the natural peptides activate several subtypes at once. MC2R is the exception, recognising ACTH but not alpha-MSH.
The standard signalling route runs through Gαs, adenylate cyclase and a rise in cAMP, followed by protein kinase A. That is not the whole story. Depending on the host cell, MC1R and MC4R can also engage Gq/11 and calcium release, and ERK1/2 phosphorylation can occur through routes that do not depend on cAMP. A compound that behaves as a full agonist in a cAMP assay may be partial on another pathway, so a single readout tells you about one branch only.
Structural changes that shift subtype preference
Most synthetic melanocortin analogs are variations on the His-Phe-Arg-Trp core, which spans positions 6 to 9 of alpha-MSH. The recurring modifications are few, and each has a clear purpose:
- Norleucine at position 4. Methionine at this position oxidises easily; norleucine keeps a similar side chain without the sulfur, removing that degradation route.
- D-phenylalanine at position 7. Flipping the stereochemistry of the core phenylalanine increases resistance to proteases and changes how the analog is ranked across subtypes.
- Lactam bridge. Linking an aspartate side chain to a lysine side chain on either side of the core locks the motif into a turn. Bridge position and ring size are among the strongest tools for tuning selectivity.
- C-terminal amide versus acid. An amide removes the terminal negative charge and generally improves stability against carboxypeptidases.
- Truncation. Shorter fragments lose classical agonism. KPV, the last three residues of alpha-MSH, lacks the core motif altogether, so it is best described as a pathway-derived fragment rather than a receptor agonist.
Three research compounds show how these pieces combine. Melanotan-1 is linear alpha-MSH carrying the Nle4 and D-Phe7 substitutions, the same sequence as the reference agonist NDP-alpha-MSH. Melanotan-II is a shortened, lactam-cyclised analog built around the core, with an amidated C-terminus. PT-141 shares that cyclic structure but ends in a free acid, so the two differ by roughly one dalton and need careful mass work to tell apart.
Where selectivity experiments go wrong
Constitutive activity and inverse agonists
This receptor family is unusual in having natural inverse agonists. MC1R is opposed by agouti signalling protein, and MC3R and MC4R by agouti-related protein, each of which can push signalling below the level seen with no ligand present. Because MC4R signals measurably on its own, the unliganded baseline has to be recorded before any agonist is added. Without that baseline, a neutral antagonist and an inverse agonist look the same, and in cells expressing very little receptor the difference may disappear entirely.
Accessory proteins
MC2R expressed on its own in a standard cell line stays trapped inside the cell and gives no signal. Co-expression of MRAP1 is required. A panel that omits it will record MC2R as unresponsive to everything, which says nothing about the compounds being tested. MRAP2 has a subtler role, modulating MC3R and MC4R output, and differences in its expression between cell lines help explain why labs disagree about MC4R data.
Species and receptor density
Ranking a compound at rodent receptors does not establish its ranking at human receptors; sequence differences in MC1R and MC4R are large enough to reorder results. High receptor expression can also inflate potency and make a partial agonist look full, so density should be stated and kept comparable across subtypes.
Building a selectivity panel that holds up
A ratio is only as reliable as the experiment that produced it. A defensible panel usually includes:
- Every subtype of interest expressed individually in the same host cell, at a stated density.
- One named reference agonist, typically NDP-alpha-MSH, used for all ratios.
- A cAMP readout plus a second pathway, such as beta-arrestin recruitment or ERK, when signalling bias is in question.
- Basal signal measured in every run.
- MRAP status declared for MC2R and, ideally, for MC3R and MC4R.
When two papers report EC50 values an order of magnitude apart for the same compound and receptor, the explanation is usually found in this list rather than in the compound.
Supplying a melanocortin panel from one order
Selectivity work compares compounds against each other, so the material itself has to be characterised consistently. A few checks matter more for this class than for most:
- Identity by mass and retention. A lactam bridge loses one water, but so does an aspartimide side product. Isomers that share a mass may separate by reversed-phase HPLC, so identity should rest on both methods.
- Light protection. Every compound built on the core motif contains tryptophan, which degrades under light. Store vials in the dark and limit bench exposure.
- Consistent normalisation. Counter-ions and residual water mean vial mass overstates peptide mass. If two analogs are normalised differently, the ratio between them is distorted before the assay begins.
- Counter-ion awareness. Residual trifluoroacetate can affect some cell-based readouts, so note the salt form in your records.
- Lot records. Buying a whole panel in one order, logging each vial group against its certificate and cap and crimp colour, and keeping to one lot per compound where possible makes later comparisons far easier to defend.
Bulk Peptides products are third-party tested for purity by HPLC, certificates are published for some products, and mix-and-match volume pricing means every vial in the cart counts toward the volume break, so a full panel can be ordered together.
All compounds mentioned are sold for in-vitro laboratory research only. They are not for human or veterinary use, and nothing in this article describes or suggests any such use.
